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ABSTRACT
The survival rates in colon cancer patients are inversely proportional to the 
number of lymph node metastases. The hypoxia-induced Epithelial to Mesenchymal 
Transition (EMT), driven by HIF1α, is known to be involved in cancer progression and 
metastasis. Recently, we have reported that miR-675-5p promotes glioma growth by 
stabilizing HIF1α; here, by use of the syngeneic cell lines we investigated the role of 
the miR-675-5p in colon cancer metastasis.
Our results show that miR-675-5p, over expressed in metastatic colon cancer 
cells, participates to tumour progression by regulating HIF1α induced EMT. MiR-675-
5p increases Snail transcription by a dual strategy: i) stabilizing the activity of the 
transcription factor HIF1α and ii) and inhibiting Snail’s repressor DDB2 (Damage 
specific DNA Binding protein 2). 
Moreover, transcriptional analyses on specimens from colon cancer patients 
confirmed, in vivo, the correlation between miR-675-5p over-expression and 
metastasis, thus identifying miR-675-5p as a new marker for colon cancer progression 
and therefore a putative target for therapeutic strategies.
INTRODUCTION
Colorectal Cancer (CRC) is one of the most 
common cancer diagnosed worldwide and still the 
most frequent cause of cancer-related mortality due to 
the development of metastases [1]. The complex set of 
events, driving the dissemination of single carcinoma 
cells from primary epithelial tumours, involves the 
phenotypic conversion commonly known as Epithelial 
to Mesenchymal Transition (EMT). [2]. Hallmark of 
the EMT process is considered the functional loss of 
E-cadherin operated by the Snail family: a family of 
zinc-finger transcription factors including Snail and Slug 
that, directly binding the E-cadherin promoter, repress 
gene transcription and stimulate the initial invasion 
[3–5].  Both Snail and Slug proteins have been implicated 
in various malignancies and associated with poor 
prognosis in carcinoma [6–9]. In colon cancer, Snail was 
found over expressed in human biopsies [10] while Slug 
expression has been proposed as a significant parameter of 
poor prognosis [11]. It is widely accepted that colon cancer 
progression and its metastasis are driven by a complex 
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set of events and, between these, a pivotal role is played 
by the hypoxia in tumour microenvironment [12]. The 
reduced O2 partial pressure in tumour microenvironment, 
prompts tumour cell to activate specific pathways that, 
driven by the transcription factor Hypoxia-inducible 
factor 1-alpha (HIF1α), induce hypermetabolism to favour 
glycolysis, resistance to chemotherapy, neo-angiogenesis 
with an increase in local vasculature and finally, tumour 
metastasis. Hypoxia induces EMT in a variety of cancers 
including colon carcinoma [13, 14] moreover, functional 
Hypoxia Response Elements (HREs) have been identified 
within Snail’s regulatory sequences [15]. 
Among the targets of HIF1α is the lncRNA H19 
[16], an imprinted non coding RNA which expression 
was found up-regulated in many tumours including 
CRC, hepatocellular carcinoma, testicular cancer, 
choriocarcinoma, osteosarcoma, esophageal cancer 
and glioma [17–20]. As already described for other 
lncRNAs, H19 can work as a microRNA sponge or 
epigenetic modulator [21, 22] moreover, it is a reservoir 
for microRNA-675 (miR-675-5p and miR-675-3p) [16] 
by which H19 seems to promote tumour growth and 
metastasis [23, 24]. Recently we demonstrated, in a glioma 
pre-clinical model, a loop between HIF1α and miR-675-5p. 
We found that miR-675-5p i) is over expressed in hypoxic 
condition, ii) it is essential to sustain hypoxic responses 
for its role in HIF1α stabilization, and in particular iii) it 
promotes hypoxia-mediated angiogenesis [25]. 
Several miRNAs have been found aberrantly 
expressed in colon cancer [26] and supposed as potential 
markers in diagnosis, prognosis and treatment of CRC [27].
In this study, we investigated the relationship 
between miR-675-5p, hypoxia and tumour metastasis 
in colon cancer. Our data indicated that miR-675-5p 
maintains a metastatic phenotype through a lncRNA H19 
independent mechanism. In particular, miR-675-5p was 
found over expressed in metastatic colon cancer patients 
while, its silencing, induced in vitro the inhibition of the 
HIF1α guided EMT, indicating the miR-675-5p as a new 
putative target and predictive marker in colon cancer.
RESULTS
MiR-675-5p inhibitor reduces metastatic 
phenotype in SW620 cells
With the aim to explore a role of miR-675-5p in 
colon cancer, we took advantage of the syngeneic cell 
lines, SW480 and SW620, that, derived respectively from 
primary tumour and lymphonodal metastasis, are an in vitro 
validated model to study tumour colon progression [28]. 
The analysis of the miRNA levels shown in Figure 1A, 
indicated higher levels of miR-675-5p in SW620 metastatic 
cells compared to non-metastatic SW480.
In order to investigate the role of miR-675-5p in 
colon cancer progression, we silenced miR-675-5p with 
a specific inhibitor in both cell lines. QRT-PCR indicated 
that both SW480 and SW620 respond to miRNA inhibitor 
by reducing the expression of Snail and Slug (master 
genes of EMT); while, we found an increase of the 
transcriptional level of the epithelial marker E-cadherin, 
known as a suppressor of invasion during carcinoma 
progression [29] (Figure 1B). Immunofluorescence 
analyses, in particular in SW620 mesenchymal-like 
cells, showed enforced expression of E-CADHERIN and 
acquisition of ZO-1 in the cell membrane after treatment 
with miR-675-5p inhibitor; meanwhile, a reduction could 
be observed in nuclear SNAIL (Figure 1C). Moreover, the 
motility assay in Figure 1D confirmed transcriptional and 
proteic data showing a significative reduction in motility 
in SW620 cells transfected with inhibitor, compared to 
scrambled control. No differences were found in SW480 
probably due to the reduced motility of these cells as 
already demonstrated by Luo et al. [30].
Overall, these data suggest a direct role of miR675-5p 
in sustaining mesenchymal phenotype and enhancing cell 
migration.
MiR-675-5p increases EMT genes transcription 
by promoting HIF1α pathway
Recently, we demonstrated in vitro and in vivo, in a 
model of glioblastoma, that miR675-5p works as a hypoxia 
mimetic factor while its inhibition reduces tumour growth 
by affecting HIF1α stabilization [25]. Hypoxia induced 
EMT is a well described process in several solid tumours, 
and EMT genes are included in the list of HIF1α’targets [31, 
32]. We investigated the possible role of HIF1α as mediator 
of miR-675-5p effects in colon carcinoma cells. As shown 
in Figure 2, miRNA inhibitor down regulated the expression 
of both HIF1α and its target VEGF in SW-cell lines (Figure 
2A, 2B). In order to i) validate the effects of miR-675-5p 
on HIF1α and ii) confirm the crosstalk between miR-675-
5p, HIF1α and EMT genes in colon carcinoma cells, we 
silenced miR-675-5p in hypoxic condition when HIF1α 
pathway is well established. First, we demonstrated that both 
cell lines respond to low O2 partial pressure by activating 
HIF1α pathway. As shown in Supplementary Figure 1, low 
oxygen condition induced, in both cell lines, an increase 
of HIF1α mRNA (Supplementary Figure 1A) and nuclear 
accumulation of HIF1α protein (Supplementary Figure 1B). 
The translocation of the hypoxic transcription factor induced 
VEGF gene expression and protein levels (Supplementary 
Figure 1C, 1D) together with HIF1α targets involved 
in EMT and migration: Snail and Slug (Supplementary 
Figure 1E). Moreover, as already found in glioblastoma, 
hypoxic condition induced a specific up regulation of 
miR-675-5p (Supplementary Figure 1F). This data indicated 
that both cell lines physiologically responded to low oxygen, 
with higher evidences in SW620 cells, as confirmed by 
transcriptional and protein analysis of HIF1α targets genes. 
While SW480 and SW620 cells similarly responded to 
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hypoxic stimuli, the treatment with the miR-675-5p inhibitor 
in hypoxia induced different effects between cell lines. The 
miR-675-5p inhibitor, while it did not affect HIF1α pathway 
in SW480 cells (Figure 2C–2F), it completely turned off 
the hypoxic response in SW620, in which we found a 
down regulation of HIF1α, both at mRNA and protein 
level (Figure 2C, 2D), together with the inhibition of its 
targets, including EMT genes (Figure 2E, 2G). In order to 
attribute these effects exclusively to miR-675-5p we silenced 
the lncRNA H19 in hypoxic SW620 cells. As shown in 
(Figure 2H, 2I) H19 silencing did not affect HIF1α, Snail 
and Slug expression in SW620 cells. These data confirmed 
a cross talk between HIF1α, miR-675-5p and EMT, in the 
metastatic SW620 cells, and identified, for the first time to 
Figure 1: miR-675-5p inhibitor reduces metastatic features and promotes epithelial phenotype. (A) Real time-PCR 
for miR-675-5p in SW480 and SW620 cells. All data were normalized for U6 and ΔΔct was expressed as relative amount of miRNAs. 
Values are presented as the mean ± SD (of three independent experiments). SW620 vs SW480 **p < 0.001. (B) Real time-PCR for 
miR-675-5p and EMT master genes: Snail, Slug and E-cadherin in SW480 and SW620 cells. Data were normalized for β-actin, while U6 
was used for miRNA normalization. ΔΔct is expressed as Fold of induction (FOI) with respect to expression in control samples. Data are the 
mean ± SD of three independent experiments. SW480 miRNA inhibitor vs SW480 scramble control: *p < 0.05; ***p < 0.0001; SW620 
miRNA inhibitor vs SW620 scramble control *p < 0.05; **p < 0.001; ***p < 0.0001. (C) Immunofluorescences and median focal plane in 
confocal analysis for E-CADHERIN, ZO-1and SNAIL in SW480 and SW620 cells treated with miR-675-5p inhibitor or scramble control, in 
blue the nuclear staining with DAPI. (D) Migration assay: Phase contrast micrographs (10×) showing the migration of SW480 and SW620 
cells pre-treated with miR-675-5p inhibitor or scramble control. Right panel: Quantification of migration by counting the number of migrated 
cells (violet) per field (n = 6); *p < 0.05. 
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our knowledge, a role of miR-675-5p independent of the 
expression of its “precursor” lncH19.  
In the light of the obtained data, further efforts 
into understanding the role of miR-675-5p in colon 
cancer progression have focused on metastatic SW620 
cells, in which the miRNA has demonstrated to play a 
dominant role. Experiments of miRNA over expression 
indicated that miR-675-5p in SW620 cells, promoted 
the activation of HIF1α pathway, this observation was 
consistent with our data obtained in glioblastoma [25]. 
The ELISA assay on nuclear extracts in Figure 3A and 
the immunofluorescence in Figure 3B, showed a nuclear 
Figure 2: miR-675-5p activates EMT genes by promoting HIF1α pathway. Real time-PCR for HIF1α (A) and VEGF-A (B) in 
SW480 and SW620 cells treated with miR-675-5p inhibitor or scramble control. Data were normalized for β-actin and ΔΔct is expressed 
as FOI with respect to expression in control samples. SW480 miRNA inhibitor vs SW480 control *p < 0.05; SW620 miRNA inhibitor vs 
SW620 control *p < 0.05 (C) Real time-PCR for HIF1α in SW480 and SW620 cells treated with miR-675-5p inhibitor or scramble control 
after 6 hours of hypoxia. Data were normalized for β-actin and ΔΔct is expressed as FOI with respect to expression in normoxia. Values 
are presented as the mean ± SD. SW620 inhibitor vs SW620 ctr **p < 0.001. ELISA assay for HIF-1α (D) and VEGFa (E) performed in 
SW480 and SW620 cells, transfected with miRNA inhibitor or scramble control, after 6 hours of hypoxia. Data are expressed as Absorbance 
(ABS) values at 450 nm. SW620 miRNA inhibitor vs SW620 scramble control **p < 0.001. Real time-PCR for hypoxia targets genes and 
EMT regulator genes (VEGF, SNAIL, SLUG) in SW480 cells (F) and SW620 cells (G) treated with miR-675-5p inhibitor or scramble 
control, after 6 hours of hypoxia. Data were normalized for β-actin and ΔΔct is expressed as FOI with respect to expression in control 
samples. SW620 inhibitor vs SW620 control **p < 0.001. (H) Real time-PCR for lncH19 and HIF1α in SW620 cells treated with siRNA 
H19 or scramble control and exposed to hypoxia for 6 hours. Data were normalized for β-actin and ΔΔct is expressed as FOI with respect to 
expression in control samples. SW620 siH19 vs SW620 control *p < 0.05;. (I) Real time-PCR for Snail and Slug in SW620 cells transfected 
with siRNA H19 or scrambled control and exposed to hypoxia for 6 hours. Data were normalized for β-actin and ΔΔct is expressed as FOI 
with respect to expression in control samples. **p < 0.001. Data are the mean ± SD of three independent experiments.
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accumulation of the transcription factor. As expected, 
nuclear increase of HIF1α allowed the transcription of 
its targets, as shown, in (Figure 3C, 3D). Moreover, an 
increase in motility has been found in SW620 cells after 
mimic transfection (Figure 3E).
Overall, these data indicated that miR-675-5p, in 
colon carcinoma, is able to favour hypoxia induced EMT 
by sustaining HIF1α pathway.
MiR-675-5p allowed EMT gene expression by 
down regulating the repressor DDB2 
Thanks to the analysis of miRNA targets through 
Target Scan, we found the damage specific DNA binding 
protein 2 (DDB2) listed between the putative miRNA 
targets (sequence of annealing is showed in Figure 4A). 
DDB2 has been described as down-regulated in high-
grade colon cancers moreover, it plays a dominant role as 
repressor of EMT genes (VEGF, Zeb1 and Snail) in colon 
cancer cells. This data let us to suppose that miR-675-5p 
might promote metastatic phenotype by coordinating 
different factors involved in regulation of EMT genes. 
To validate DDB2 as a target for miR-675-5p in colon 
cancer metastatic cells, mRNA levels have been analysed 
in SW620 cells transfected with the miR-675-5p mimic 
or inhibitor. As shown in Figure 4A, DDB2 mRNA is 
inhibited by miRNA mimic while, it is over expressed in 
SW620 cells transfected with the miRNA inhibitor. Western 
Figure 3: Gain of function suggests a critical role of miR-675-5p on colon cancer aggressiveness. (A) ELISA assay for 
HIF-1α performed in SW620 cells nuclear extracts after mimic or scramble-control transfection. Data are expressed as Absorbance (ABS) 
values at 450nm. SW620 mimic vs SW620 scramble control **p < 0.001. Data are the mean ± SD of three independent experiments. 
(B) Immunofluorescences and median focal plane of confocal analysis for HIF1α (red) in SW620 cells treated with miR-675-5p mimic or 
scrambled control, in blue the nuclear staining with DAPI. (C) Real-time PCR for HIF1α targets gene (Snail, Slug, VEGF, VEGFR-2) from 
SW620 cells after miR-675-5p mimic or scramble control transfection. Data were normalized for β-actin and ΔΔct is expressed as FOI of 
indicated genes after mimic transfection with respect to scramble control. (D) ELISA assay for VEGF levels in supernatants from SW620 
cell lines 18 hours after mimic and scramble control transfection. Data are expressed as pg/ml of soluble VEGF. SW620 mimic vs SW620 
scramble control ***p < 0,0001. Data are the mean ± SD of three independent experiments. (E) Migration assay: Phase contrast micrographs 
(10×) showing the migration of SW620 cells pre-treated with mimic miR-675-5p and scramble control. Right panel: Quantification of 
motility established by counting the number of migrated cells (violet) per field; SW620 mimic vs SW620 scramble control *p <  0.05.
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blot analysis showed the dual effect caused by the miRNA 
inhibitor treatment in SW620 which induced the increase 
of DDB2 protein while reduced HIF1α (Figure 4B). These 
data were confirmed by western blot on nuclear extracts, 
which revealed also a reduction of nuclear SNAIL (data 
not shown). Overall, our data indicated that miR-675-5p 
promotes tumour progression in colon carcinoma regulating 
the expression of EMT genes by at least two independent 
mechanisms:  the activation of the transcription factor 
HIF1α and the inhibition of the repressor factor DDB2.
Metastatic colon cancer express higher level of 
miR-675-5p compared to non-metastatic
In order to validate the in vivo the data obtained in 
the in vitro model, the miR-675-5p levels were analysed 
in colon specimens obtained from patients with different 
stages of colon carcinoma. The Real time PCR in 
Figure 5A revealed, for the first time to our knowledge, 
a correspondence between lymphonode metastasis (TNM 
stage) and miR-675-5p expression. In particular, we 
found higher levels of miR-675-5p in specimens from 
colon cancer patients (n11) with lymphonodal metastasis 
(N > 0) compared to patients (n11) without lymphonodal 
compromission N = 0. As expected, and consistent with 
the data in literature, patients with lymphonodal metastasis 
showed also higher levels of lncRNA H19 (Figure 5B), 
HIF1α and its target VEGF while lower levels of DDB2 
expression were found (Supplementary Figure 2).
DISCUSSION
Colon cancer-related mortality is associated with 
high-grade disease, strictly connected to the number of 
metastasis [33]. Our data revealed a role of miR-675-
5p in maintaining metastatic phenotype. We found, both 
in vitro and in specimens from human colon cancer 
patients, that metastatic colon cancer cells, overexpress 
miR-675-5p if compared to non-metastatic cells, consisting 
with data obtained in other tumours (glioblastoma, 
esophageal, squamous cell carcinoma, osteosarcoma 
[24, 34, 35]). Furthermore, our studies indicated that 
miR675-5p expression sustains metastatic phenotype through 
a hypoxia induced EMT. Matouk et al. highlighted a critical 
role of lncRNA H19 in breast cancer progression indicating 
“the axis H19/miR675 as a part of EMT programs”. They 
suggested that H19 may suppress E-cadherin expression by 
up-regulating Slug, via a mechanism that involves miR675 
and which mediator has to be defined [36]. Recently, Roy et al. 
identified in DDB2 a suppressor of EMT for colon cancer cells 
with a significant decrease in high-grade colon cancer . They 
found that DDB2 constitutively represses EMT master genes, 
in SW480 cells, while its depletion, in SW620 cells, correlates 
with the mesenchymal phenotype [37]. Our data indicated that 
miR-675-5p promotes EMT genes expression, Snail in 
particular, through a dual strategy: the stabilization of 
a transcription factor (HIF1α) and the inhibition of a 
transcriptional repressor (DDB2). However, further analysis 
are required to better define the molecular crosstalk between 
these actors in order to promote the mesenchymal phenotype.
Even if colon carcinoma cell lines present a basal 
activation of HIF1α pathways [38], the experiments 
in hypoxic condition allowed to identify substantial 
differences between metastatic and non-metastatic cells, 
in response to low oxygen partial pressure. In SW620 
cells, HIF1α nuclear accumulation reaches higher level 
compared to SW480 and this is reflected in a substantial 
increase of its targets genes, suggesting a greater ability 
Figure 4: miR-675-5p down regulates the repressor DDB2. (A) Left: predicted seed sequence for miR-675-5p on DDB2 gene. 
Right: Real-time PCR for DDB-2 gene from SW620 cells after 18 hours of miR-675-5p mimic or miR-675-5p inhibitor or scramble control 
transfection. Data were normalized for β-actin and ΔΔct is expressed as FOI with respect to scramble control. SW620 mimic and inhibitor 
vs SW620 **p < 0,001. Data are the mean ± SD of three independent experiments. (B) Western blot for DDB2, HIF1α and β-actin in SW620 
cells after 18 hours of miR-675-5p scramble control or inhibitor transfection. 
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of metastatic cells to activate hypoxic responses that, as 
known, are implicated into the promotion of angiogenesis, 
chemoresistance and tumour metastasis [39–41]. Our 
data indicated that miR-675-5p levels were increased 
in hypoxic condition and, only in metastatic cells, 
miR675-5p is required to maintain HIF1α pathways, 
thus demonstrating the existence of different control 
mechanisms of hypoxia between metastatic and non 
metastatic cells. While the inhibition of miR-675-5p was 
able, per se, to completely turn off hypoxic responses in 
SW620, it did not affect cells from primary tumour; these 
data enforced the concept that different strategies have to 
be adopted in order to treat high grade or low grade colon 
cancer. 
MATERIALS AND METHODS
Cell culture and reagents
SW480 and SW620 cells were routinely maintained 
in RPMI supplemented with 10% heat-inactivated fetal 
bovine serum, penicillin and streptomycin (50 IU/ml), 
2 mM glutamine (Euroclone, UK). Cells were maintained 
in a humidified atmosphere of 5% of CO2 at 37°C. To 
perform hypoxia experiments, both cell lines were seeded 
at 10,000 cells/cm2 and incubated in a “Hypoxic Chamber” 
containing 1% O2 gas mixture for 6 hours. 
Cell transfection
For cell transfection, Attractene Transfection Reagent 
(cat. number 1051531, Qiagen) was used following 
manufactory’s indication. Briefly, SW480 and SW620 
cells were seeded at 10,000 cells/cm2 and transfected with 
15pmoles/ml of hsa-miR-675-5p inhibitor (cat. number 
4464084, Life Technologies, Italy), hsa-miR-675-5p mimic 
(cat.number 4464066, Life Technologies) or scrambled 
negative control (cat. number 4464058, Life Technologies). 
Eighteen hours after transfection, the medium was collected 
and the cells processed for following assays.
TransAM Kit
An ELISA-based kit (TransAM Kit, Vinci-
Biochem, Italy) was used to detect and quantify HIF-1α 
transcriptional factor activity following manufacturer’s 
instructions. Briefly, nuclear extracts were firstly prepared 
using the Nuclear Extract Kit (Vinci-Biochem) and 
8 µg of the samples were added to the coated plate and 
analysed at 450 nm with Gen5 Microplate Collection & 
Analysis Software Data (BioTek Instruments, Inc.®). Data 
were expressed as HIF-1α protein content in total nuclear 
extract (Absorbance).
ELISA assay
VEGF concentration was quantified using the 
ELISA kit (VEGF Human ELISA KitNovex® cat. 
numberKHG011, Life Technologies), according to 
manufacturer’s protocol. SW480 and SW620 -conditioned 
medium was collected after hypoxia treatment or 
transfection with miR-675-5p inhibitor or mimic. Data 
were expressed as VEGF concentration in pg/ml. 
RNA extraction and real-time PCR
Total RNA was extracted using the commercially 
available illustraRNAspin Mini Isolation Kit (GE 
Healthcare, Italy), according to manufacturer’s 
instructions. Tissue RNAs was extracted using the 
commercially available PureLink FFPE Total RNA 
Isolation Kit (Invitrogen cat.number 45-7015). Human 
colorectal cancer specimens (n = 22) were collected 
from the pathology archives of the Human Pathology 
Figure 5: miR -675-5p expression in human colon carcinoma progression. (A) Real time-PCR for miR-675-5p in specimens 
obtained from colon carcinoma patients with or without metastasis. All data were normalized for U6 and ΔΔct was expressed as FOI of 
analysed genes in N > 0 vs N = 0. Values are presented as the mean ± SD. ***p < 0.001 gene expression in tumour N > 0 vs tumour N = 0. 
For statistical analysis t-test or one- or two-way analysis of variance (ANOVA), followed by Dunnett’s or Bonferroni’s multiple comparison 
test, were performed using Prism 4(GraphPad SoftwareInc., CA, USA). (B) Real-time PCR for lncH19 in specimens obtained from colon 
carcinoma patients with or without metastasis. Data were normalized for β-actin and ΔΔct was expressed as FOI of analysed genes in 
N > 0  vs N = 0.
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Section, Ospedali Riuniti Villa Sofia-Cervello (Palermo) 
in accordance with the Declaration of Helsinki and with 
the policy of the Institute. RNA was reverse-transcribed 
to cDNA using the High Capacity cDNA Reverse 
Transcription Kit (Applied Biosystem, USA).  Real-time 
PCR was performed in duplicates for each data point, and 
the oligonucleotides used are described in Table 1.
Changes in the target mRNA content relative to 
housekeeping gene (β-actin) were determined with the 
ΔΔct Method. For miRNA expression, 250 ng of RNA was 
reverse transcripted according to manufacturer’s instructions 
(cat.number 4366596, TaqManMicroRNA Reverse 
Transcription, Applied Biosystem). Taqman probes were 
used to analyse: miR-675-5p (cat.number 4440887,Applied 
Biosystem), miR-675-3p (cat.number 4427975, Applied 
Biosystem), U6 (cat.number  4427975 Applied Biosystem), 
and H19 (Hs00262142_g1 Life Technologies). Changes in 
the target miRNA content relative to housekeeping U6 were 
determined with the ΔΔct Method.
Silencing of lncH19 
SW620 cells were grown at a density of 
100.000 cells/well in a 6 wells plate, and transfected 
by using Attractene Transfection Reagent (cat. 
number.1051531, Quiagen) for 6 hours with 0.2 mg/ml H19 
siRNA  (SR319206B Origene Technologies) or scramble 
negative control (SR30004 Origene Technologies) at the 
same dose following manufacturer’s indications.
Western blotting
SDS-PAGE and Western Blotting (WB) were 
performed according to standard protocols. Briefly, SW620 
cells after transfection with miR-675-5p inhibitor were 
lysed in lysis buffer containing 15 mM Tris/ HCl pH7.5, 
120 mM NaCl, 25 mM KCl, 1 mM EDTA, 0.5% Triton 
X100, Halt Protease Inhibitor Single-Use cocktail (100X, 
ThermoScientifc). Whole lysate (15 µg per lane) were 
separated using 4–12% NovexBis-Tris SDS-acrylamide 
gels (Invitrogen), electro-transferred on Nitrocellulose 
membranes (Bio-Rad), and immunoblotted with the 
appropriate antibodies. The antibodies against the following 
proteins were used: HIF1α (Anti-HIF 1α, Rabbit Polyclonal 
cat. number 1854599, Millipore), DDB2 (DDB2 (H-127): 
sc-25368, Santa Cruz Biotechnology, INC.), SNAIL (Snail 
(C15D3) Rabbit mAb#3879, Cell Signaling), and β-Actin 
(Monoclonal anti-β-actin, A5316 Sigma). All secondary 
antibodies were obtained from Thermo Fisher Scientific. 
Immunofluorescence was detected using ChemiDoc Biorad 
acquisition instrument.
Immunofluorescence analysis
Immunocytochemistry was done on PFA 4% fixed 
cells, and stained with the following primary antibodies: 
anti-E-Cadherin (BD Biosciences 610181), anti-SNAIL 
(sc-28199, Santa Cruz Biotechnology, INC.) and anti-
ZO-1 (ZO-1 (C-19): sc-8146, Santa Cruz Biotechnology, 
INC.); the secondary antibodies were Alexa-Fluor 488 and 
Alexa-Fluor 594, from Molecular Probes. The nuclei were 
stained with NucRed® Live 647 (Catalog number: R37106, 
Life Technologies), and preparations were analysed by 
confocal microscopy (Nikon A1). 
Transwell cell migration assay
Cell migration assay was performed as described 
by [42, 43]. Briefly, 18 hours after transfection, cells 
were trypsinized and adjusted to 8 × 105 cells/ml of cell 
suspension, 200 µl from this solution, were seeded into the 
upper chamber of transwells (Cell culture insert, Corning, 
Table 1: Gene primers used to study gene expression profiling
Gene Primer forward Primer reverse
VEGF CGAGGGCCTGGAGTGTGT CGCATAATCTGCATGGTGATG
VEGFR CGGTCAACAAAGTCGGGAGA CAGTGCACCACAAAGACACG
H19 GCACCTTGGACATCTGGAGT TTCTTTCCAGCCCTAGCTCA
HIF-1α TGATTGCATCTCCATCTCCTACC GACTCAAAGCGACAGATAACACG
E-CADHERIN GAGGAGAGCGGTGGTCAAAG GTTCAGGGAGCTCAGACTAG
SLUG CATGCCTGTCATACCACAAC GGTGTCAGATGGAGGAGGG
SNAIL GCGAGCTGCAGGACTCTAAT CCCGCAATGGTCCACAAAAC
DDB-2 ATCAAAGGGATTGGAGCTGGAG GCTCCATCGGGACTGAAACA
B-ACTIN ATCAAGATCATTGCTCCTCCTGA CTGCTTGCTGATCCACATCTG
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cat. Number 353097), while 800 µl of medium with 
20%FBS was added in the lower chamber. Cells were then 
cultured at 37 °C for 48 h and the cells on the surface of 
the up chamber were removed with cotton swaps and the 
cells under the surface of the low chamber were stained 
with crystal violet (0.1%). Migrated cells were examined 
under an inverted microscope and photographed at 20× 
magnification. The number of cells were measured manually 
with IMAGE-J software (http://rsbweb.nih.gov/ij/).
Statistical analysis
In vitro experiments were repeated three times, 
giving reproducible results. Data are presented as mean 
values ± standard deviation (SD) of three independent 
experiments. For statistical analysis t-test or one- or two-
way analysis of variance (ANOVA), followed by Dunnett’s 
or Bonferroni’s multiple comparison test, were performed 
using Prism 4 (GraphPad SoftwareInc., CA, USA).
CONCLUSIONS
For the first time to our knowledge, we identified 
the leading role of miR-675-5p in hypoxia induced 
EMT, that is independent from “its precursor” the 
lncRNA-H19. Moreover, our data obtained from CRC 
specimens indicated miR-675-5p as putative target and 
new prognostic marker for CRC. However, further studies 
are required to identify the molecular mechanisms that 
increase  miR-675-5p levels in metastatic cells.
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